...
首页> 外文期刊>Endoscopy International Open >International multicenter comparative trial of transluminal EUS-guided biliary drainage via hepatogastrostomy vs. choledochoduodenostomy approaches
【24h】

International multicenter comparative trial of transluminal EUS-guided biliary drainage via hepatogastrostomy vs. choledochoduodenostomy approaches

机译:经肝胃造瘘术与胆总管十二指肠造瘘术经腔内EUS引导胆管引流的国际多中心比较试验

获取原文
           

摘要

Background and study aims: Endoscopic ultrasound-guided biliary drainage (EUS-BD) can be performed entirely transgastrically (hepatogastrostomy/EUS-HG) or transduodenally (choledochoduodenostomy/EUS-CDS). It is unknown how both techniques compare. The aims of this study were to compare efficacy and safety of both techniques and identify predictors of adverse events. Patients and methods: Consecutive jaundiced patients with distal malignant biliary obstruction who underwent EUS-BD at multiple international centers were included. Technical/clinical success, adverse events, stent complications, and survival were assessed. Results: A total of 121 patients underwent EUS-BD (CDS 60, HG 61). Technical success was achieved in 112 (92.56?%) patients (EUS-CDS 93.3?%, EUS-HG 91.8?%, P?=?0.75). Clinical success was attained in 85.5?% of patients who underwent EUS-CDS group as compared to 82.1?% of patients who underwent EUS-HG (P?=?0.64). Adverse events occurred more commonly in the EUS-HG group (19.67?% vs. 13.3?%, P?=?0.37). Both plastic stenting (OR 4.95, 95?%CI 1.41?–?17.38, P?=?0.01) and use of non-coaxial electrocautery (OR 3.95, 95?%CI 1.16?–?13.40, P?=?0.03) were independently associated with adverse events. Length of hospital stay was significantly shorter in the CDS group (5.6 days vs. 12.7 days, P?
机译:背景和研究目的:内镜超声引导下胆汁引流术(EUS-BD)可以完全经胃(肝胃造瘘术/ EUS-HG)或经十二指肠(胆总管十二指肠吻合术/ EUS-CDS)进行。尚不知道这两种技术如何比较。这项研究的目的是比较两种技术的有效性和安全性,并确定不良事件的预测因子。患者和方法:包括在多个国际中心接受EUS-BD的连续性黄疸伴远端恶性胆道梗阻的患者。评估技术/临床成功,不良事件,支架并发症和生存率。结果:总共121例患者接受了EUS-BD(CDS 60,HG 61)。 112名患者(92.56%)获得了技术上的成功(EUS-CDS 93.3%,EUS-HG 91.8%,P <= 0.75)。接受EUS-CDS组的患者中有85.5%的患者获得了临床成功,而接受EUS-HG的患者中则有82.1%的患者获得了临床成功(P = 0.64)。在EUS-HG组中,不良事件的发生率更高(19.67 %%对13.3 %%,P <= 0.37)。塑料支架置入术(OR 4.95,95%CI 1.41?–?17.38,P?=?0.01)和使用非同轴电灼(OR 3.95,95 %% CI 1.16?–?13.40,P?=?0.03)与不良事件独立相关。 CDS组的住院时间明显缩短(5.6天vs. 12.7天,P <0.001)。平均随访时间为151±±159天。 EUS-CDS组1年支架通畅的可能性更大[0.98(95%CI 0.76?–0.96)vs 0.60(95%CI 0.35?–0.78)],但总体通畅率没有显着差异。两组之间的中位生存时间无差异(P≤0.36)结论:EUS-CDS和EUS-HG都是治疗ERCP失败后远端胆道梗阻的有效且安全的技术。但是,CDS与住院时间短,支架通畅性提高以及与手术和支架相关的并发症少有关。应在可行的情况下放置金属支架,并应尽可能避免使用非同轴电灼术,因为塑料支架和非同轴电灼术均独立于不良事件的发生。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号